The recent surge in investments into specialized pharmaceutical companies, particularly those focusing on experimental therapies and complex drug development programs, has fueled what some are calling "High Investor Pharma." While the potential for game-changing treatments and impressive returns is clear, the connected risks are also significant… Read More